Subscribe
Sign in
Subscribe
Sign in
GlobalData
GlobalData

Pharma

CAR-T therapies need to overcome current limitations to unlock promising treatment possibilities for solid tumors, says GlobalData

CAR-Ts are revolutionizing the treatment of blood cancers, such as B-cell acute lymphocytic leukemia. However, their success has not yet extended to the realm of solid tumors, as no CAR-T therapy has advanced beyond Phase II in one of these indications. Overcoming current limitations and expanding the reach of CAR-T therapeutics could unlock promising new […]
Read more

Sibeprenlimab’s priority review highlights potential to differentiate in IgAN space, says GlobalData

Otsuka Pharmaceutical recently announced that the FDA has accepted for review the Biologics License Application (BLA) for sibeprenlimab, which acts as A Proliferation Inducing Ligand (APRIL) inhibitor in development for immunoglobulin A (IgA) nephropathy (IgAN). This followed sibeprenlimab’s 2024 FDA breakthrough designation for the same indication. The BLA was supported by the Phase III VISIONARY […]
Read more

GlobalData forecasts ADC NSCLC market to reach $3.9 billion in 2032

Despite the FDA first approving Pfizer’s antibody-drug conjugate (ADCs) Mylotarg (gemtuzumab ozogamicin) in 2000, it was not until 2022 for non-small-cell lung cancer (NSCLC) to see its first ADC approval, AstraZeneca’s and Daiichi Sankyo’s Enhertu (trastuzumab deruxtecan), for human epidermal growth factor receptor (HER) 2-mutated patients. Following this approval, the ADC market in NSCLC is […]
Read more

KDCA and SK bioscience forge ahead to shield South Korea against future pandemic influenza threats, says GlobalData

South Korea has launched the Priority Infectious Disease Pandemic Preparedness Rapid R&D Support Program, led by the Korea Disease Control and Prevention Agency (KDCA) in collaboration with SK bioscience. This proactive initiative is expected to significantly strengthen and prepare the nation against emerging influenza threats, says GlobalData, a leading data and analytics company. This government-led […]
Read more

Ionis’ Olezarsen to achieve global sales of approximately $849 million by 2032, forecasts GlobalData

Ionis Pharmaceuticals has announced positive topline results from the ESSENCE study evaluating Olezarsen in individuals with moderate hypertriglyceridemia who are at risk of atherosclerotic cardiovascular disease (ASCVD). Upon approval, the drug is projected to achieve global sales of approximately $849 million by 2032, according to GlobalData, a leading data and analytics company. The study met […]
Read more

Sanofi and Regeneron AIM4 trial may redefine timing of biologic use in asthma care, says GlobalData

Sanofi and Regeneron Pharmaceuticals (Regeneron) have launched the Phase IIIb/IV AIM4 trial at the 2025 American Thoracic Society (ATS) International Conference to evaluate whether earlier initiation of dupilumab improves outcomes in patients with moderate-to-severe asthma compared to standard stepwise escalation with high-dose inhaled corticosteroids. The study reflects a growing shift toward personalized, biomarker-driven asthma management […]
Read more

Healthcare professionals recognize virtual care role in empowering patients, reveals GlobalData

As digital health technologies continue to evolve, healthcare professionals (HCPs) are increasingly recognizing the role of virtual care in empowering patients. Against this backdrop, a significant majority of HCPs believe trends like telemedicine and remote care have given patients more control over their health management, underscoring the growing importance of virtual care in modern healthcare, […]
Read more

Real-world data backs anti-IL-5 use in COPD with comorbid asthma, says GlobalData

Anti–IL-5 biologics, such as mepolizumab and benralizumab, have demonstrated significant efficacy in reducing moderate and severe exacerbations in patients with both asthma and chronic obstructive pulmonary disease (COPD), according to new real-world data presented at the 2025 American Thoracic Society (ATS) International Conference. These findings reinforce the therapeutic potential of eosinophil-targeting agents in patients with […]
Read more

GSK’s Nucala highlights IL-5 inhibition in reducing COPD exacerbations in eosinophilic patients, says GlobalData

GSK’s Nucala (mepolizumab) demonstrated a consistent reduction in exacerbation rates among patients with eosinophilic chronic obstructive pulmonary disease (COPD), irrespective of prior severe event history, according to findings presented at the 2025 American Thoracic Society (ATS) International Conference. These results further solidify the role of IL-5 inhibition in biomarker-driven COPD management, says GlobalData, a leading […]
Read more

Tezepelumab’s trial results strengthen potential for biomarker-driven biologic therapies in COPD, says GlobalData

Tezepelumab, a thymic stromal lymphopoietin (TSLP) inhibitor developed by AstraZeneca and Amgen, demonstrated significant reductions in chronic obstructive pulmonary disease (COPD) exacerbations among eosinophilic subgroups, regardless of chronic bronchitis status, according to new post hoc findings presented at the 2025 American Thoracic Society (ATS) International Conference. These results further support the potential for biomarker-driven biologic […]
Read more

ICON retains lead as most active CRO in Q1 2025, reveals GlobalData

ICON maintains its place as the most active contract research organization (CRO) for Q1 2025 and Russia keeps its spot with the most clinical trials initiated in Europe despite the ongoing war with Ukraine, according to a report by GlobalData, a leading data and analytics company. GlobalData’s latest report “Q1 2025 Clinical Trials: CRO, Sponsor […]
Read more

Record-breaking FDA biosimilar approvals to create opportunities for drug developers and manufacturers, says GlobalData

FDA biosimilar approvals reached a record 19 in 2024, with projections indicating that 2025 could surpass this milestone trend. This presents a golden opportunity for Contract Manufacturing Organizations (CMOs) specializing in biologics, as more blockbuster drugs approach patent expiration and regulatory barriers to entry diminish, says GlobalData, a leading data and analytics company. Kathryn Kinch, […]
Read more

HIV market to surpass $32 billion across 7MM in 2033, forecasts GlobalData

The human immunodeficiency virus (HIV) market across the seven major markets (7MM*) is forecast to grow at a compound annual growth rate (CAGR) of 1.9% from $26.5 billion in 2023 to $32.1 billion in 2033, forecasts GlobalData, a leading data and analytics company. GlobalData’s report, “Human Immunodeficiency Virus (HIV): Seven-Market Drug Forecast,” reveals that market […]
Read more

GLP-1R agonists poised to redefine chronic disease treatment beyond diabetes and obesity, says GlobalData

GLP-1 receptor agonists, once focused on treating diabetes and obesity, are now emerging as potential treatments for a broader range of chronic conditions, including Alzheimer’s disease. As evidence builds around their wider therapeutic benefits, particularly in targeting insulin resistance, drug developers are accelerating efforts to expand their use and potentially transform how multiple high-burden diseases […]
Read more

Three CAR-T therapies to capture over 70% of T-Cell immunotherapy market in 2025, forecasts GlobalData

T-cell immunotherapies (TCI) are redefining cancer care, with chimeric antigen receptor T-cell (CAR-T) therapies witnessing significant momentum. In 2025, just three drugs- Carvykti by Legend Biotech, Yescarta by Gilead Sciences, and Breyanzi by Bristol-Myers Squibb (BMS)– are expected to capture over 70% of the global T-cell immunotherapy market, according to GlobalData, a leading data and […]
Read more

Finerenone continues to impress in diabetic kidney disease space, says GlobalData

In a recent study conducted by Navaneethan and colleagues and published in the International Society of Nephrology, the cardiovascular and kidney benefits of Bayer’s Kerendia (finerenone) are maintained regardless of acute changes in estimated glomerular filtration rate (eGFR) following treatment initiation in patients with chronic kidney disease (CKD) and type 2 diabetes (T2D). This comprehensive […]
Read more

Shionogi’s cefiderocol shows improved outcomes with early use in treating gram-negative infections, reports GlobalData

Japan-based Shionogi has shared new real-world evidence showing its antibiotic cefiderocol leads to better outcomes when used early to treat serious gram-negative bacterial infections. Presented at European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Global 2025 conference in Vienna, the Retrospective Cefiderocol Chart Review (PROVE) study found that earlier use of cefiderocol, rather than […]
Read more
1 … 9 10 11 12 13 … 110